| Date | Title | Description |
| 27.11.2024 | Apheresis in Cellular Therapies: Unlocking Quality for CAR T and Stem Cell Treatments, Upcoming Webinar Hosted by Xtalks | www.nybce.org/comprehensive-cell-solutions
In this free webinar, learn about the role of apheresis in sourcing high-quality starting materials for cellular therapies like CAR T-cell treatments and stem cell transplants. Attendees will gain ... |
| 20.05.2024 | Cordlife announces arrest of one more director amid investigations into mishandling of cord blood units | Listen to this article
Cordlife announces arrest of one more director amid investigations into mishandling of cord blood units
1 min
New: You can now listen to articles.
Sorry, the audio is unavailable right now. Please try again later.
Thi... |
| 15.05.2019 | With new cancer drugs, the challenge is finding where cost, value meet | “It’s something that we’ve always struggled with,” Tada said in a phone interview, referring to the question of value versus cost.
For example, compared with the US, drugmakers can charge whatever they want to, which works well for their bo... |
| 09.05.2019 | Don’t miss this innovation in cancer treatment conference in Philadelphia | A panel discussion will explore how precision medicine can be the key to population health. Experts from Cancer Treatment Centers of America, Color and other organizations will talk about the synergies between precision medicine and populat... |
| 05.02.2015 | Former Dendreon CEO launches stealth next-gen immunotherapy startup in Seattle | Dendreon is known for launching Provenge, a prostate cancer drug that was the first-ever immunotherapy treatment to get regulatory approval. Dendreon’s also known for filing for bankruptcy this past November, because of the drug’s poor perf... |
| 07.03.2012 | No IPO for immunotherapy company Argos Therapeutics | But the public markets have remained cool to life science IPOs. Merrimack Pharmaceuticals, a a Cambridge, Massachusetts firm developing cancer treatments, last month postponed its $80 million IPO. Chapel Hill, North Carolina-based Cempra Ph... |
| 16.02.2012 | Life sciences companies make pharma pitches, hope for hits with investors | Heat Bio. Heat’s lead drug program is an experimental lung cancer treatment in phase 2 clinical trials. Heat Bio’s proprietary technology reprograms tumor cells to pump out antigens to fight disease. CEO Jeff Wolf said that when the company... |
| 08.09.2011 | Dendreon Whacks 500 Jobs, 25% of Workforce, After Missing Sales Goal | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
[Updated: 1:15 pm PT] People at Seattle-based Dendreon (NASDAQ: DNDN) have been waiting for five weeks to find out how many employees would lose their jobs, after the company ... |
| 07.09.2011 | Provenge fallout leads Dendreon to end GSK supply pact | The impact of slow sales of Dendreon‘s (NASDAQ:DNDN) prostate cancer treatment Provenge is reaching pharma giant GlaxoSmithKline (NYSE:GSK).
Seattle biotech company Dendreon is terminating a supply contract it signed a year ago that called ... |
| 29.07.2011 | What Argos Therapeutics plans to do with $86M from an IPO | Proceeds from the stock offering will be used to finance trials that will test lead product candidate AGS-003 in combination with Pfizer (NYSE:PFE) drug sunitinib, which is already used in treating kidney cancer patients. AGS-003 is being s... |
| 13.05.2011 | Immunotherapy technology from Argos seeks partner for kidney cancer trials | Immunotherapy induces a patient’s own immune system to fight disease. Argo’s technology, called Arcelis, works by taking the RNA from the patient’s cancer and pairing it with the patient’s dendritic cells. Dendritic cells tell the immune sy... |
| 27.04.2010 | Morning Read: The case for private-practice primary care | Highlights of the important and the interesting from the world of healthcare:
The case for private-practice primary care: There’s been lots of handwringing in recent years about the slow and continuing disappearance of private-practice phys... |
| 07.05.2009 | Dendreon’s Hiring Binge, Calistoga’s Venture Round, ZymoGenetics Unloads Drugs, & More Seattle-Area Life Sciences News | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Biotech is a volatile business, and this week hammered home that point. Seattle had layoffs at one important device company (Pathway Medical), a hiring boom at another (Dendre... |
| 12.08.2008 | Dendreon Gives Update on Clinical Trials of Prostate Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
As Luke reported a couple weeks ago, Seattle-based Dendreon is in the midst of a crucial clinical trial of its cancer drug, Provenge, against prostate cancer. Interim results ... |
| 12.10.2007 | Bellicum’s prostate-cancer vaccine: Dendritic cells served with a genetic twist | For a few brief months earlier this year, Dendreon‘s Provenge looked like it might become the first cancer vaccine approved by the FDA, despite some iffy data supporting its effectiveness. The fate of Provenge now hangs in the balance follo... |
| 10.10.2007 | Life sciences briefing: Wednesday, Oct. 10, 2007 | Featured companies: 20/20 GeneSystems, Bellicum Pharmaceuticals, Cumbre Pharmaceuticals, Dara BioSciences, Enterprise Partners Venture Capital, Fermentas, International, Iasis Medical, New Leaf Venture Partners, Point Therapeutics, Power Me... |
| 13.08.2007 | Weekend update: That cold, cold artificial heart, Dendreon-related skulduggery, congressional earmarks, and more | (UPDATED: See below.)
Catching up on a few life-science related items you may have missed over the weekend:
If you prick a cyborg, does he not bleed? — The WaPo’s Joel Garreau brings us this fascinating story about Peter Houghton, the first... |
| 06.06.2007 | Patients, CEOs and ideologues vs. evidence-based medicine | The first time you hear it, “evidence-based medicine” sounds like one of those goofily redundant phrases like “animated cartoon” or “past experience.” Aren’t doctors always carrying out studies of one sort or another? Isn’t medicine evidenc... |
| 09.05.2007 | No immunity for Dendreon’s cancer vaccine | (UPDATED: See below.) For almost two months, it has seemed that the FDA might be ready to approve an entirely new attack on cancer — a “cancer vaccine” that immunizes patients with tumor fragments in order to activate the body’s immune defe... |
| - | Don’t miss this innovation in cancer treatment conference in Philadelphia | It feels like we’re on the cusp of great things in the development of cancer treatments. A wave of immunotherapy and gene therapy approvals could point the way forward in treating and curing certain forms of cancer. Pharma and technology co... |
| - | No IPO for immunotherapy company Argos Therapeutics | Immunotherapy company Argos Therapeutics has pulled back on its plans for an initial public offering and leaves it needing to find another way to finance phase 3 clinical trials for its novel kidney cancer treatment.
In a letter filed with ... |
| - | Life sciences companies make pharma pitches, hope for hits with investors | Life sciences companies presenting at CED’s Life Science Conference largely stuck to script. Prepared remarks. PowerPoint presentations. After 11 minutes on stage, another presenter took their place.
Immunotherapy company Heat Biologics bro... |
| - | Former Dendreon CEO launches stealth next-gen immunotherapy startup in Seattle | Dendreon may be on its last legs, but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences, seeding about $1.3 million into the company throug... |
| - | Immunotherapy technology from Argos seeks partner for kidney cancer trials | Immunotherapy company Argos Therapeutics has developed a new technology that could set it apart from other biotechnology cancer treatments — an approach that’s completely personalized to the patient and also costs less. But that’s just the ... |
| - | With new cancer drugs, the challenge is finding where cost, value meet | In the last two decades, numerous new drugs have come to market and turned some cancers that used to be death sentences into manageable or even curable diseases. But one significant hurdle remains: They’re often incredibly expensive. So the... |
| - | What Argos Therapeutics plans to do with $86M from an IPO | Immunotherapy company Argos Therapeutics plans to start enrolling patients in a phase 3 kidney cancer trial for its lead candidate in the fourth quarter.
But first, Argos needs money. The company has just over $3 million in cash on hand, ac... |
| - | Provenge fallout leads Dendreon to end GSK supply pact | The impact of slow sales of Dendreon‘s (NASDAQ:DNDN) prostate cancer treatment Provenge is reaching pharma giant GlaxoSmithKline (NYSE:GSK).
Seattle biotech company Dendreon is terminating a supply contract it signed a year ago that called ... |
